Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
Diabetes is on the rise at an alarming rate in the United States. An estimated 9.3% of the US population, or 29.1 million people, are affected by diabetes. Furthermore, approximately 37% of all US adults (51% of people aged ≥65 years) have prediabetes, a condition that greatly increases their risk for developing diabetes. The prevalence of diabetes is projected to increase from 1 in 10 adults today to 1 in 3 adults by 2050, based on current trends and the aging of the population over the next few decades. Type 2 diabetes mellitus, a type of diabetes characterized by insulin resistance and the gradual decline in the ability of the pancreas to produce insulin, accounts for an estimated 90% to 95% of all cases of diabetes.
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma
Melanoma, although not the most common skin cancer in the United States, is the most deadly. Based on data collected between 2004 and 2010, the 5-year survival rate for Americans with metastatic melanoma remains very low—only 16%—for all ages and races, and both sexes. The National Cancer Institute has estimated that 21.3 in 100,000 people will be diagnosed with melanoma of the skin in the United States in 2014. More than 9700 patients are estimated to die from melanoma in the same time frame.
Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis, a debilitating lung disease, affects approximately 128,100 patients in the United States, with 48,000 new cases diagnosed annually. Idiopathic pulmonary fibrosis is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults (ie, aged 50-75 years). The disease is characterized by progressive worsening of dyspnea (shortness of breath) and lung function, as well as a poor prognosis. In fact, the median survival for patients with idiopathic pulmonary fibrosis in the United States is 2.5 to 3.5 years after diagnosis, with the disease claiming an estimated 40,000 lives annually.
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis
Psoriatic arthritis and psoriasis, often referred to as psoriatic diseases, are autoimmune diseases characterized by chronic inflammation, tissue and organ involvement, and the accelerated growth cycle of skin cells. Both psoriatic arthritis and psoriasis impose a substantial physical, emotional, and economic burden on the millions of individuals in the United States who are affected by these conditions.
Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections
An acute bacterial skin and skin-structure infection (ABSSSI) is a bacterial infection of the skin with a lesion size of ≥75 cm2, which is measured by the area of redness, edema, or induration. The types of infections that comprise ABSSSIs include cellulitis or erysipelas, major cutaneous abscesses, and wound infections; these infections can be life-threatening and may require hospitalization and surgery.
Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea
Rosacea is a chronic and progressive skin condition characterized by episodes of remission and exacerbations of its many cutaneous symptoms, including flushing, facial erythema, telangiectasia, edema, papules, pustules, ocular lesions, and rhinophyma. Approximately 16 million individuals in the United States are affected by rosacea. The incidence of rosacea is increasing with aging. Rosacea is more frequently observed in women than in men; however, men with rosacea often have more disfiguring skin changes than women.
Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes affects 25.8 million individuals in the United States, an estimated 8.3% of the US population. Furthermore, approximately 79 million US adults aged >20 years have prediabetes. Based on the aging of the US population and its projected increasing incidence in the coming decades, diabetes is estimated to affect 1 in 3 US adults by 2050. Effective preventive strategies, particularly in high-risk individuals, may reduce the projected increase in the prevalence of diabetes.
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes, a chronic disease that is often accompanied by multiple comorbidities and health complications, is the seventh leading medical cause of death in the United States. In fact, the mortality rate for patients with diabetes is 1.5 times higher than for individuals without diabetes. Diabetes affects an estimated 29.1 million individuals in the United States—an alarming 9.3% of the US population. In addition, an estimated 37% of US adults aged ≥20 years have prediabetes, according to the 2009-2012 National Health and Nutrition Examination Survey data. The prevalence of diabetes is projected to increase from 1 in 10 adults today to 1 in 3 adults by 2050, coinciding with the aging of the baby boom generation during the next few decades. Type 2 diabetes mellitus accounts for approximately 90% to 95% of all cases of diabetes.
Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
Multiple myeloma, also referred to as myeloma, is a malignant neoplasm of plasma cells in the bone marrow that leads to bone destruction and bone marrow failure. According to the American Cancer Society, an estimated 26,850 new cases of myeloma will be diagnosed in 2015, and 11,240 deaths will be attributed to myeloma.
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection
Approximately 130 million to 170 million individuals worldwide, including 3.2 million Americans, are infected with chronic hepatitis C virus (HCV), making it the most common blood-borne disease. Chronic HCV infection is a silent epidemic; the disease can remain quiescent for decades before clinically significant symptoms appear.
Page 2 of 3
Results 11 - 20 of 27
Results 11 - 20 of 27